Astria Therapeutics (ATXS) said Wednesday that navenibart, its potential hereditary angioedema treatment, has received Orphan Medicinal Product Designation from the European Commission.
The status provides incentives for the development of products for diagnosing, preventing or treating rare life-threatening or very serious conditions in the EU, according to the company.
Astria said that based on initial results from a phase 1b/2 clinical trial, navenibart showed a favorable safety and tolerability profile and reduced monthly attack rates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。